If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Use in Patients With Hypothyroidism or Hyperthyroidism
Tirzepatide has not been studied in patients with hypothyroidism or hyperthyroidism.
cFAQ
cFAQ
US_cFAQ_TZP028_HYPOTHYROIDISM_HYPERTHYROIDISM
en-US
Detailed Information
There is no information on the use of tirzepatide in people with hypothyroidism or hyperthyroidism because this has not been studied. People with controlled endocrine abnormalities were not excluded from tirzepatide clinical trials. However, patients were excluded if they had a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises) in the opinion of the investigator.
Date of Last Review: February 05, 2021
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon – Friday, 9am-7pm (EST), excluding holidays